RetractedArticleBritish journal of cancer2011
Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab.
A Gualberto et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
43 papers cite it
this papertrialcites it